Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Autoimmune Dis. 2008 Nov 11;5:6. doi: 10.1186/1740-2557-5-6.

Controversies in the antiphospholipid syndrome: can we ever stop warfarin?

Author information

  • 1The Lupus Research Unit, the Rayne Institute, St. Thomas' Hospital, London SE17EH, UK. ana.fonseca@fcm.unl.pt

Abstract

Patients with antiphospholipid syndrome are at increased risk for recurrent arterial and venous thrombosis and therefore benefit from long term warfarin therapy. The optimal duration of warfarin therapy after a first venous thromboembolic event is however a matter of some controversy and many questions remain unanswered. After reviewing and analysing the available evidence, we discuss some common scenarios in everyday clinical practice where treatment decisions are difficult.

PMID:
19014462
[PubMed]
PMCID:
PMC2632629
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Write to the Help Desk